Literature DB >> 1557063

Neurotoxicity of levodopa on catecholamine-rich neurons.

M A Mena1, B Pardo, M J Casarejos, S Fahn, J García de Yébenes.   

Abstract

The human neuroblastoma cells NB69 are a catecholamine-rich cell line with pharmacological properties similar to dopamine neurons. This cell line was used to study the neurotoxicity of levodopa on catecholamine neurons. Levodopa, at 50 x 10(-6) M or higher concentrations, produced a dose- and time-dependent reduction in the number of live cells, [3H]thymidine uptake, levels of protein and DNA, and an enhancement of the quinone formation. This is a specific effect of levodopa since it did not happen in NB69 cells incubated with equimolar concentrations of leucine and tryptophan. Treatment with deprenyl, an inhibitor of monoamine oxidase type B, partially prevented levodopa neurotoxicity, suggesting that the mechanism of toxicity was, at least in part, related to an increase in the metabolism of dopamine catalyzed by monoamine oxidase.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1557063     DOI: 10.1002/mds.870070105

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  18 in total

Review 1.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Pharmacological treatment of Parkinson's disease.

Authors:  A Münchau; K P Bhatia
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

3.  Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole.

Authors:  P M Carvey; S Pieri; Z D Ling
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

4.  L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cells.

Authors:  Branden J Stansley; Bryan K Yamamoto
Journal:  Neuropharmacology       Date:  2012-11-27       Impact factor: 5.250

Review 5.  Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.

Authors:  R G Fariello
Journal:  Drugs       Date:  1998       Impact factor: 9.546

6.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease.

Authors:  G Walkinshaw; C M Waters
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

Review 7.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 8.  The role of astroglia on the survival of dopamine neurons.

Authors:  María Angeles Mena; Sonsoles de Bernardo; Maria José Casarejos; Santiago Canals; Eulalia Rodríguez-Martín
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

9.  Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice.

Authors:  Markus M Forsberg; Risto O Juvonen; Petra Helisalmi; Jukka Leppänen; Joseph A Gogos; Maria Karayiorgou; Pekka T Männistö
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-17       Impact factor: 3.000

10.  Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.

Authors:  M J LaVoie; T G Hastings
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.